Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis.
Zivadinov R, Bergsland N, Jakimovski D, Weinstock-Guttman B, Lorefice L, Schoonheim MM, Morrow SA, Ann Picone M, Pardo G, Zarif M, Gudesblatt M, Nicholas JA, Smith A, Hunter S, Newman S, AbdelRazek MA, Hoti I, Riolo J, Silva D, Fuchs TA, Dwyer MG, Hb Benedict R. Zivadinov R, et al. Among authors: zarif m. Neuroimage Clin. 2024;42:103609. doi: 10.1016/j.nicl.2024.103609. Epub 2024 Apr 27. Neuroimage Clin. 2024. PMID: 38718640 Free PMC article.
De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate.
Gudesblatt M, Bumstead B, Buhse M, Zarif M, Morrow SA, Nicholas JA, Hancock LM, Wilken J, Weller J, Scott N, Gocke A, Lewin JB, Kaczmarek O, Mendoza JP, Golan D. Gudesblatt M, et al. Among authors: zarif m. Adv Ther. 2024 Aug;41(8):3059-3075. doi: 10.1007/s12325-024-02902-0. Epub 2024 Jun 11. Adv Ther. 2024. PMID: 38861218 Free PMC article.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.
Effects of mesenchymal stromal cells and human recombinant Nerve Growth Factor delivered by bioengineered human corneal lenticule on an innovative model of diabetic retinopathy.
Pelusi L, Hurst J, Detta N, Pipino C, Lamolinara A, Conte G, Mastropasqua R, Allegretti M, Di Pietrantonio N, Romeo T, El Zarif M, Nubile M, Guerricchio L, Bollini S, Pandolfi A, Schnichels S, Mandatori D. Pelusi L, et al. Among authors: el zarif m. Front Endocrinol (Lausanne). 2024 Oct 15;15:1462043. doi: 10.3389/fendo.2024.1462043. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39473506 Free PMC article.
104 results